Physician profile
Vincent Gemma
NPI 1790195303
$8,761.83
in general payments reported to CMS, 2019-2025
11 companies · $5,832 in 2025
The $5,832 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.50 · 2021: $61.76 · 2023: $39.92 · 2024: $2,777 · 2025: $5,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $3,457 · Food and Beverage: $692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $3,457.25 |
| Food and Beverage | $692.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,278.06 | 2024-2025 | |
| Globus Medical, INC. | $1,137.29 | 2024 | Corbel |
| Medtronic, INC. | $151.86 | 2025 | Progrip |
| Integra Lifesciences Corporation | $44.93 | 2020-2021 | |
| Tela Bio, INC. | $33.31 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $26.49 | 2025 | Exparel |
| Daiichi Sankyo INC. | $24.78 | 2023 | Enhertu |
| Angiodynamics, INC. | $22.08 | 2020 | |
| Genentech USA, INC. | $15.95 | 2025 | Actemra |
| Braintree Laboratories, INC. | $15.14 | 2023 | Suflave |
| Mallinckrodt Hospital Products INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Gemma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.